

Resolutions at the extraordinary general meeting in Medivir on 20 November 2014

Voluntary redemption programme

The extraordinary general meeting in Medivir Aktiefbolag (publ) on 20 November 2014 resolved, in accordance with the board of directors' proposal, on a voluntary redemption programme comprising reduction of the statutory reserve, reduction of the share capital for repayment to the shareholders, and bonus issue without issuance of new shares.

The redemption programme will be effected by redemption of a maximum of 4,465,717 shares, whereof 94,285 series A shares and 4,371,432 series B shares. For each share in the company, the shareholder receives one redemption right. Redemption rights received for series A shares entitle the holder to redeem series A shares and redemption rights received for series B shares entitle the holder to redeem series B shares. All holders of redemption rights receive an equal right to redeem shares, regardless of share class. The reduction is made by way of repayment to the shareholders with a maximum amount of SEK 625,200,380.

Preliminary record day for receiving redemption rights is 9 February 2015. The application period for redemption will commence on the third trading day after the record day and runs for fourteen calendar days. Customary trading with redemption rights and redemption shares in respect of series B shares will be arranged.

For more information, please contact:

Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292

Medivir is required under the Swedish Securities Market Act to make the information in this press release public. The information was submitted for publication at 11.45 CET on 20 November 2014.

About Medivir

Medivir is an emerging and profitable research-based pharmaceutical company with an established marketing and sales organisation in the Nordic region with a broad portfolio of prescription pharmaceuticals. Medivir receives royalties from Johnson & Johnson on the global sales of the hepatitis C pharmaceutical, Olysio®. In addition, revenues for sales of Olysio in the Nordic region are generated through the company's own sales and marketing organisation. Medivir's research and development portfolio of pharmaceuticals is based on the company's expertise within protease inhibitor design and nucleoside/nucleotide science. The company's research and development focus is within infectious diseases and oncology and the on-going clinical projects in osteoarthritis and neuropathic pain. Medivir is listed on the Nasdaq Stockholm Mid Cap List.